Sf rowasa (ulcerative colitis) forecast and market analysis to 2022

60 %
40 %
Information about Sf rowasa (ulcerative colitis) forecast and market analysis to 2022

Published on June 27, 2014

Author: lindahauck18

Source: slideshare.net

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Published: Feb 2014 Single User PDF: US$ 3495 Corporate User PDF: US$ 10485 Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 1© ReportsnReports.com / Contact sales@reportsandreports.com

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson’s (J&J’s) Simponi and Takeda’s Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively. Each sfRowasa unit is a 60mL rectal suspension that delivers up to 4g of mesalamine to the left side of the colon. sfRowasa sulfite-free (sf) formulation is the first sulfite-free rectal suspension available for the treatment of UC. The results of a study published in the American Journal of Gastroenterology in 1998 showed that products containing sulfites may be the cause of a possible flare in UC patients (Levine et al, 1998, Year). Hydrogen sulfide is a luminally-acting, bacterially-derived molecule that is harmful to cells and has been implicated in UC. Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 2© ReportsnReports.com / Contact sales@reportsandreports.com

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Scope - Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on SfRowasa including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for SfRowasa from 2012 to 2022. - Sales information covered for the US Request a Sample of this report @ http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=282204 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 3© ReportsnReports.com / Contact sales@reportsandreports.com

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 Reasons to buy - Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of SfRowasa performance - Obtain sales forecast for SfRowasa from 2012-2022 in the US Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=282192 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 4© ReportsnReports.com / Contact sales@reportsandreports.com

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 List of Tables Table 1: Genetic Factors That Confer a Predisposition to UC 13 Table 2: Typical Symptoms of UC 15 Table 3: Truelove and Witts UC Severity Index 19 Table 4: UCDAI 20 Table 5: Treatment Guidelines for UC Used in the 10MM 21 Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013 22 Table 7: Leading Treatments for UC, 2014 28 Table 8: Product Profile - sfRowasa 29 Table 9: sfRowasa SWOT Analysis, 2014 30 Table 10: Global Sales Forecasts ($m) for sfRowasa, 2012-2022 31 Table 11: Annual Cost of Therapy for 5-ASAs ($) 38 Table 12: Physicians Surveyed, By Country 40 Buy a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=282192 . Order this report by calling +1 888 391 5441 or Send an email to sales@reportsandreports.com with your contact details and questions if any. 5© ReportsnReports.com / Contact sales@reportsandreports.com

Add a comment

Related pages

sfRowasa (Ulcerative Colitis) - Forecast and Market ...

... (Ulcerative Colitis) - Forecast and Market Analysis to 2022. ... During the forecast period from 2012-2022, ... Overview of Ulcerative Colitis, ...
Read more

sfRowasa (Ulcerative Colitis) - Forecast and Market ...

sfRowasa (Ulcerative Colitis) - Forecast and Market Analysis to 2022 sfRowasa ... Forecast and Market Analysis to 2022. Lowest Prices Guaranteed: Length ...
Read more

sfRowasa (Ulcerative Colitis) - Forecast and Market ...

... (Ulcerative Colitis) - Forecast and Market Analysis to 2022. ... During the forecast period from 2012–2022, ... Overview of Ulcerative Colitis, ...
Read more

sfRowasa (潰瘍性大腸炎) 2022年までの予測 ...

... (Ulcerative Colitis) - Forecast and Market Analysis to 2022. ... sfRowasa (潰瘍性大腸炎) 2022 ... 6.4 SWOT Analysis 30 6.5 Forecast 31
Read more

sfRowasa(潰瘍性大腸炎):市場分析と予測 ...

... (Ulcerative Colitis) - Forecast and Market Analysis ... (Ulcerative Colitis) - Forecast and Market ... Analysis to 2022. Summary. During the forecast ...
Read more

[시장보고서]sfRowasa(궤양성 대장염) : 예측 ...

... (Ulcerative Colitis) - Forecast and Market Analysis to 2022: ... Forecast and Market Analysis to 2022: ... (sf) formulation is the ...
Read more

Market Analysis for Apokyn (Parkinson’s Disease) to 2022

... to 2022. Tweet. Information ... Information about Market Analysis for Apokyn (Parkinson’s ... org/apokyn-parkinsons-disease-forecast-and-market ...
Read more

sfRowasa(潰瘍性大腸炎) - 預測與市場分析 - GII

... (Ulcerative Colitis) - Forecast and Market ... (Ulcerative Colitis) - Forecast and Market Analysis ... During the forecast period from 2012-2022, ...
Read more